Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry

Presley BCJ-VS, Logan BK (2013) Analysis of synthetic cannabinoids in botanical material: a review of analytical methods and findings. Forensic Sci Rev 25(1/2):27–46

De Brabanter N, Deventer K, Stove V, Van Eenoo P (2013) Synthetic cannabinoids: general considerations. P Belg Roy Acad Med 2:218–234

Drug Enforcement Administration, Department of Justice (2011) Schedules of controlled substances: temporary placement of three synthetic cathinones into schedule I. Fed Regist 76:11075

United States Congress (2012) Synthetic drug abuse prevention act of 2012. https://www.govtrack.us/congress/bills/112/s3190/text

Arntson A, Ofsa B, Lancaster D, Simon JR, McMullin M, Logan B (2013) Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens. J Anal Toxicol 37:284–290

Barnes AJ, Young S, Spinelli E, Martin TM, Klette KL, Huestis MA (2014) Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine. Forensic Sci Int 241C:27–34

Castaneto MS, Desrosiers NA, Ellefsen K, Anizan S, Martin TM, Klette KL, Huestis MA (2014) Method validation of the biochip array technology for synthetic cannabinoids detection in urine. Bioanalysis (in press)

Wohlfarth A, Scheidweiler KB, Chen X, Liu HF, Huestis MA (2013) Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. Anal Chem 85(7):3730–3738

Sundstrom M, Pelander A, Angerer V, Hutter M, Kneisel S, Ojanpera I (2013) A high-sensitivity ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry (UHPLC-HR-TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine. Anal Bioanal Chem 405(26):8463–8474

Kronstrand R, Brinkhagen L, Birath-Karlsson C, Roman M, Josefsson M (2014) LC-QTOF-MS as a superior strategy to immunoassay for the comprehensive analysis of synthetic cannabinoids in urine. Anal Bioanal Chem 406(15):3599–3609

Guale F, Shahreza S, Walterscheid JP, Chen HH, Arndt C, Kelly AT, Mozayani A (2013) Validation of LC-TOF-MS screening for drugs, metabolites, and collateral compounds in forensic toxicology specimens. J Anal Toxicol 37(1):17–24

Möller I, Wintermeyer A, Bender K, Jübner M, Thomas A, Krug O, Schänzer W, Thevis M (2011) Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test Anal 3(9):609–620

Adamowicz P, Zuba D, Sekula K (2013) Analysis of UR-144 and its pyrolysis product in blood and their metabolites in urine. Forensic Sci Int 233(1–3):320–327

Grigoryev A, Kavanagh P, Melnik A, Savchuk S, Simonov A (2013) Gas and liquid chromatography-mass spectrometry detection of the urinary metabolites of UR-144 and its major pyrolysis product. J Anal Toxicol 37(5):265–276

Kavanagh P, Grigoryev A, Melnik A, Simonov A (2012) The identification of the urinary metabolites of 3-(4-methoxybenzoyl)-1-pentylindole (RCS-4), a novel cannabimimetic, by gas chromatography-mass spectrometry. J Anal Toxicol 36(5):303–311

Grigoryev A, Savchuk S, Melnik A, Moskaleva N, Dzhurko J, Ershov M, Nosyrev A, Vedenin A, Izotov B, Zabirova I, Rozhanets V (2011) Chromatography-mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures. J Chromatogr B 879(15–16):1126–1136

Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Huestis MA (2014) Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS. Bioanalysis 6(9):1187–1200

Wohlfarth A, Gandhi AS, Pang S, Zhu M, Scheidweiler KB, Huestis MA (2014) Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5 F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Anal Bioanal Chem 406(6):1763–1780

Gandhi AS, Zhu M, Pang S, Wohlfarth A, Scheidweiler KB, Liu HF, Huestis MA (2013) First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry. AAPS J 15(4):1091–1098

Gandhi AS, Zhu M, Pang S, Wohlfarth A, Scheidweiler KB, Huestis MA (2014) Metabolite profiling of RCS-4, a novel synthetic cannabinoid designer drug, using human hepatocyte metabolism and TOF-MS. Bioanalysis 6(11):1471–1485

Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Liu HF, Huestis MA (2013) First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin Chem 59(11):1638–1648

Gandhi AS, Wohlfarth A, Zhu M, Pang S, Castaneto M, Scheidweiler KB, Huestis MA (2014) High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes. Drug Test Anal. doi: 10.1002/dta.1662

Gambaro V, Arnoldi S, Bellucci S, Casagni E, Dell'Acqua L, Fumagalli L, Pallavicini M, Roda G, Rusconi C, Valoti E (2014) Characterization of in vitro metabolites of JWH-018, JWH-073 and their 4-methyl derivatives, markers of the abuse of these synthetic cannabinoids. J Chromatogr B 957:68–76

De Brabanter N, Esposito S, Tudela E, Lootens L, Meuleman P, Leroux-Roels G, Deventer K, Van Eenoo P (2013) In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200. Rapid Commun Mass Spectrom 27(18):2115–2126

Sobolevsky T, Prasolov I, Rodchenkov G (2012) Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test Anal 4(10):745–753

Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH (2012) Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in “K2/Spice”: identification of novel cannabinoid receptor ligands. Drug Metab Dispos 40(11):2174–2184

Grigoryev A, Melnik A, Savchuk S, Simonov A, Rozhanets V (2011) Gas and liquid chromatography–mass spectrometry studies on the metabolism of the synthetic phenylacetylindole cannabimimetic JWH-250, the psychoactive component of smoking mixtures. J Chromatogr B 879(25):2519–2526

Jang M, Yang W, Shin I, Choi H, Chang H, Kim E (2014) Determination of AM-2201 metabolites in urine and comparison with JWH-018 abuse. Int J Legal Med 128(2):285–294

Hutter M, Broecker S, Kneisel S, Auwärter V (2012) Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in ‘herbal mixtures’ using LC-MS/MS techniques. J Mass Spectrom 47(1):54–65

Moran CL, Le V-H, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, Prather PL, James LP, Radominska-Pandya A, Moran JH (2011) Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem 83(11):4228–4236

Matuszewski BK, Constanzer ML, Chavez-Eng CM (2003) Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 75(13):3019–3030

University of Michigan (2013) Monitoring the future drug press release: American teens more cautious about using synthetic drugs. http://www.monitoringthefuture.org//pressreleases/13drugpr_complete.pdf

Patton AL, Chimalakonda KC, Moran CL, McCain KR, Radominska-Pandya A, James LP, Kokes C, Moran JH (2013) K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci 58(6):1676–1680

Thornton SL, Wood C, Friesen MW, Gerona RR (2013) Synthetic cannabinoid use associated with acute kidney injury. Clin Toxicol 51:189–190

Murphy T (2013) Acute kidney injury associated with synthetic cannabinoid use—multiple states, 2012. Morbid Mortal Wkly Rep 62(6)

Bhanushali GK, Jain G, Fatima H, Leisch LJ, Thornley-Brown D (2013) AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol 8(4):523–526

Winstock AR, Barratt MJ (2013) The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol Clin Exp 28(4):390–393

Mir A, Obafemi A, Young A, Kane C (2011) Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 128(6):e1622–e1627

Seely KA, Lapoint J, Moran JH, Fattore L (2012) Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 39(2):234–243

Wu AH, Gerona R, Armenian P, French D, Petrie M, Lynch KL (2012) Role of liquid chromatography-high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology. Clin Toxicol 50(8):733–742

Scheidweiler KB, Huestis MA (2014) Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-tandem mass spectrometry. J Chromatogr A 1327:105–117

Malik-Wolf B, Vorce S, Holler J, Bosy T (2014) Evaluation of abalone beta-glucuronidase substitution in current urine hydrolysis procedures. J Anal Toxicol 38(3):171–176

European Monitoring Centre for Drugs and Drug Addiction (2014) European Drug Report 2014: trends and developments. http://www.emcdda.europa.eu/publications/edr/trends-developments/2014